Sequence editing by Apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance

Design:Promiscuous guanine (G) to adenine (A) substitutions catalysed by apolipoprotein B RNA-editing catalytic component (APOBEC) enzymes are observed in a proportion of HIV-1 sequences in vivo and can introduce artifacts into some genetic analyses. The potential impact of undetected lethal editing on genotypic estimation of transmitted drug resistance was assessed. Methods:Classifiers of lethal, APOBEC-mediated editing were developed by analysis of lentiviral pol gene sequence variation and evaluated using control sets of HIV-1 sequences. The potential impact of sequence editing on genotypic estimation of drug resistance was assessed in sets of sequences obtained from 77 studies of 25 or more therapy-naive individuals, using mixture modelling approaches to determine the maximum likelihood classification of sequences as lethally edited as opposed to viable. Results:Analysis of 6437 protease and reverse transcriptase sequences from therapy-naive individuals using a novel classifier of lethal, APOBEC3G-mediated sequence editing, the polypeptide-like 3G (APOBEC3G)-mediated defectives (A3GD) index', detected lethal editing in association with spurious ‘transmitted drug resistance’ in nearly 3% of proviral sequences obtained from whole blood and 0.2% of samples obtained from plasma. Conclusion:Screening for lethally edited sequences in datasets containing a proportion of proviral DNA, such as those likely to be obtained for epidemiological surveillance of transmitted drug resistance in the developing world, can eliminate rare but potentially significant errors in genotypic estimation of transmitted drug resistance.

[1]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[2]  Anne-Mieke Vandamme,et al.  Edinburgh Research Explorer Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1 , 2007 .

[3]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[4]  M. Malim,et al.  APOBEC-mediated viral restriction: not simply editing? , 2007, Trends in biochemical sciences.

[5]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[6]  S. Khoo,et al.  Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'. , 2007, AIDS.

[7]  Paul Sandstrom,et al.  HIV-1 drug resistance surveillance using dried whole blood spots , 2007, Antiviral therapy.

[8]  Tulio de Oliveira,et al.  Molecular Epidemiology: HIV-1 and HCV sequences from Libyan outbreak , 2006, Nature.

[9]  W. Heneine,et al.  Evaluation of Dried Blood Spots for Human Immunodeficiency Virus Type 1 Drug Resistance Testing , 2006, Journal of Clinical Microbiology.

[10]  D. Bennett.  The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world , 2006, Current opinion in infectious diseases.

[11]  C. Moore,et al.  Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation , 2006, Journal of Virology.

[12]  S. Wain-Hobson,et al.  Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication , 2006, Nucleic acids research.

[13]  Y. Fujiyama,et al.  Emergence of Antiretroviral Theraphy Resistance-Associated Primary Mutations Among Drug-Naive HIV-1-Infected Individuals in Rural Western Cameroon , 2006, Journal of acquired immune deficiency syndromes.

[14]  B. Walker,et al.  Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. , 2006, Journal of virological methods.

[15]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[16]  L. M. Mansky,et al.  Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. , 2006, AIDS reviews.

[17]  S. Khoo,et al.  Will ART rollout in Africa drive an epidemic of drug resistant HIV? , 2006, AIDS.

[18]  E. Delaporte,et al.  Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study , 2006, AIDS.

[19]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[20]  B. Cullen.  Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors , 2006, Journal of Virology.

[21]  P. Wright,et al.  Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.

[22]  Thomas Lengauer,et al.  ROCR: visualizing classifier performance in R , 2005, Bioinform..

[23]  A. Harrison,et al.  A statistical model for HIV-1 sequence classification using the subtype analyser (STAR) , 2005, Bioinform..

[24]  N. Wolfe,et al.  Outbreak of a West African Recombinant of HIV-1 in Tashkent, Uzbekistan , 2005, Journal of acquired immune deficiency syndromes.

[25]  F. Ceccherini‐Silberstein,et al.  High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations , 2005, Journal of Virology.

[26]  D. Ho,et al.  Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.

[27]  L. Ivers,et al.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Liddament,et al.  The Retroviral Hypermutation Specificity of APOBEC3F and APOBEC3G Is Governed by the C-terminal DNA Cytosine Deaminase Domain* , 2005, Journal of Biological Chemistry.

[29]  Stéphane Hué,et al.  Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Tara L. Kieffer,et al.  G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo , 2005, Journal of Virology.

[31]  Erin N. Bodine,et al.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.

[32]  Brian T. Foley,et al.  HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences, 2005 , 2005 .

[33]  B. Berkhout,et al.  APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. , 2004, AIDS.

[34]  F. Ceccherini‐Silberstein,et al.  Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure , 2004, AIDS.

[35]  M. Malim,et al.  Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins , 2004, Current Biology.

[36]  M. Emerman,et al.  Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.

[37]  M. Robb,et al.  The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. , 2004, AIDS research and human retroviruses.

[38]  B. Preston,et al.  Purifying Selection Masks the Mutational Flexibility of HIV-1 Reverse Transcriptase* , 2004, Journal of Biological Chemistry.

[39]  Reuben S Harris,et al.  Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. , 2004, Journal of molecular biology.

[40]  M. Essex,et al.  Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. , 2003, AIDS research and human retroviruses.

[41]  M. Malim,et al.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif , 2003, Nature Medicine.

[42]  Huynh Tan Tien,et al.  HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs. , 2003, AIDS research and human retroviruses.

[43]  Noah Kiwanuka,et al.  Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. , 2002, AIDS research and human retroviruses.

[44]  U. Alam,et al.  Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants , 2002, AIDS.

[45]  B. Foley,et al.  Phylogenetic analysis of reverse transcriptase in antiretroviral drug-naive Korean HIV type 1 patients. , 2001, AIDS research and human retroviruses.

[46]  F. McCutchan,et al.  Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells , 2001, Journal of Virology.

[47]  Bette T. Korber,et al.  Detecting hypermutations in viral sequences with an emphasis on G A hypermutation , 2000, Bioinform..

[48]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[49]  A. Meyerhans,et al.  Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes , 1991, Journal of virology.